MedPath

Vitamin C

Generic Name
Vitamin C
Brand Names
Ascor, Citranatal B-calm Kit, Concept Ob, Ferralet 90, Hematogen, Infuvite, Infuvite Pediatric, Moviprep, Mvc-fluoride, Mvi Pediatric, Natafort, Plenvu, Pregvit, Vitafol-one
Drug Type
Small Molecule
Chemical Formula
C6H8O6
CAS Number
50-81-7
Unique Ingredient Identifier
PQ6CK8PD0R
Background

A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.

Indication

Used to treat vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant. It has also been suggested to be an effective antiviral agent.

Associated Conditions
Common Cold, Deficiency, Vitamin A, Deficiency, Vitamin D, Fever, Flu caused by Influenza, Folate deficiency, Iron Deficiency (ID), Iron Deficiency Anemia (IDA), Oral bacterial infection, Scurvy, Vitamin C Deficiency, Vitamin Deficiency
Associated Therapies
Nutritional supplementation, Vitamin supplementation
Clinical Trials
Related News

REMAP-CAP Trial Shows Hydrocortisone Reduces Mortality in Severe Community-Acquired Pneumonia

• A landmark randomized clinical trial has demonstrated that hydrocortisone significantly reduces mortality in patients with severe community-acquired pneumonia, providing crucial evidence for steroid use in this population. • The REMAP-CAP Corticosteroid Domain study, published in Intensive Care Medicine, offers definitive guidance on corticosteroid therapy timing and dosing for critically ill pneumonia patients. • These findings represent a major advancement in critical care medicine, potentially changing standard treatment protocols for severe pneumonia cases in intensive care settings worldwide.

High-Dose Vitamin C Doubles Survival in Pancreatic Cancer Patients in Phase 2 Trial

• A Phase 2 clinical trial reveals that high-dose intravenous vitamin C, when combined with chemotherapy, doubles the overall survival rate for patients with late-stage metastatic pancreatic cancer. • The study demonstrated an extension in overall survival from eight to sixteen months and progression-free survival from four to six months with the addition of high-dose vitamin C. • Researchers found that high doses of vitamin C generate hydrogen peroxide, which selectively kills cancer cells, and patients tolerated chemotherapy better with the addition of vitamin C. • Experts emphasize the need for larger, randomized Phase 3 trials to validate these findings before widespread clinical adoption, while remaining cautiously optimistic about vitamin C's potential.

Topical Human Platelet Extract Shows Similar Benefits to Vitamin C for Hand Photoaging

• A clinical trial comparing topical human platelet extract (HPE) and vitamin C found both treatments similarly effective in improving photoaging of the hands. • After 12 weeks, both HPE and vitamin C reduced brown spots and wrinkles and improved skin luminosity and color evenness. • By 26 weeks, brown spot fractional area decreased by approximately 23% with HPE and 26% with vitamin C, with no statistically significant difference between the two. • HPE may be a more reliable and skin-friendly alternative to vitamin C due to the latter's potential to increase photosensitivity and disrupt skin's pH balance.

McGuff Pharmaceuticals Receives FDA Approval for Santa Ana Manufacturing Facility

• McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA. • The approval allows MPI to expand its capabilities as a CMO/CDMO, offering end-to-end drug development and manufacturing services to pharmaceutical companies. • MPI plans to increase production of its Ascorbic Acid Injection (ASCOR) to meet growing national and international demand following the facility's approval. • The new facility will handle NDA and ANDA labeled injectable products, contract manufactured products, and clinical trial products, including sterile and hazardous drugs.

McGuff Pharmaceuticals Receives FDA Approval for Santa Ana Manufacturing Facility

• McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA. • The FDA approval allows MPI to expand its capabilities as a CMO/CDMO, offering integrated drug development and manufacturing services to pharmaceutical companies. • The new facility will support the production of NDA and ANDA labeled injectable products, contract manufactured products, and clinical trial products, including sterile and hazardous drugs. • MPI plans to increase production of its FDA-approved Ascorbic Acid Injection (ASCOR) to meet growing customer demands both nationally and internationally.

McGuff Pharmaceuticals Receives FDA Approval for Santa Ana Manufacturing Facility

• McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA. • The FDA approval allows MPI to expand its capabilities as a CMO/CDMO, offering integrated drug development and manufacturing services to pharmaceutical companies. • The new facility will support the production of NDA and ANDA labeled injectable products, contract manufactured products, and clinical trial products, including sterile and hazardous drugs. • MPI plans to increase production of its FDA-approved Ascorbic Acid Injection (ASCOR) to meet growing customer demands following the facility's approval.

Microbiome Modulation with SIM01 Shows Promise for Long COVID Treatment in Randomized Trial

• A randomized, triple-blind, placebo-controlled clinical trial by Chinese University of Hong Kong demonstrated that SIM01, an oral microencapsulated live bacteria formula, significantly improved long COVID symptoms compared to placebo. • The RECOVERY study of 463 patients showed SIM01 effectively addressed digestive problems, fatigue, difficulty concentrating, memory loss, and general unwellness through restoration of gut microbiome diversity. • Researchers identified this as the first clinical trial demonstrating gut microbiome modulation can improve neurological symptoms of long COVID, highlighting the importance of the gut-brain axis in treatment approaches.

University of Minnesota Trial Finds Hydroxychloroquine No Better Than Placebo in Preventing COVID-19

A University of Minnesota trial has concluded that hydroxychloroquine is no more effective than a placebo in preventing COVID-19 after exposure, with 40% of participants experiencing non-serious side effects.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy